To Top

Pipeline

Overview

Multiple links image

CM24NT219

CM24

CM24 is a first-in-class clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with significant potential to treat multiple cancers.

NT219

NT219 is a first-in-class, novel small molecule targeting both IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.

CONSENSI®

Consensi®️ is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.

Publications

NT219

CM24

Skip to content